Advertisement

Amino Acid Products

[29 April 2016]

Products Affected - Description

All presentations are currently available

Reason for the Shortage

  • Baxter was experiencing increased demand.
  • BBraun was experiencing increased demand.
  • Hospira had amino acid products on back order due to manufacturing delays.

Available Products

Aminosyn (sulfite-free) injection, Hospira
3.5%, 1000 mL flexible container, 6 count (NDC 00409-4196-05)
8.5%, 500 mL flexible container, 12 count (NDC 00409-4187-03)
10%, 500 mL flexible container, 12 count (NDC 00409-4191-03)
10%, 1000 mL flexible container, 6 count (NDC 00409-4191-05)
8.5% with electrolytes, 500 mL flexible container, 12 count (NDC 00409-4203-03)
 
Aminosyn II (sulfite-free) injection, Hospira
8.5%, 500 mL flexible container, 12 count (NDC 00409-4162-03)
10%, 500 mL flexible container, 12 count (NDC 00409-4164-03)
10%, 1000 mL flexible container, 6 count (NDC 00409-4164-05)
10%, 2000 mL flexible container, 6 count (NDC 00409-7172-17)
15%, 2000 mL flexible container, 6 count (NDC 00409-7171-17)
8.5% with electrolytes, 500 mL flexible container, 12 count (NDC 00409-4171-03)
 
Aminosyn-PF (sulfite-free) injection, Hospira
7%, 500 mL flexible container, 12 count (NDC 00409-4178-03)
10%, 1000 mL flexible container, 6 count (NDC 00409-4179-05)
 
Clinisol (sulfite-free) injection, Baxter
15%, 500 mL flexible container, 24 count (NDC 00338-0502-03)
15%, 2000 mL flexible container, 6 count (NDC 00338-0502-06)
 
FreAmine III injection, BBraun
10%, 1000 mL glass container, 6 count (NDC 00264-9010-55)
 
Plenamine injection, BBraun
15%, 1000 mL glass container, 6 count (NDC 00264-3200-55)
 
Premasol (sulfite-free) injection, Baxter
6%, 500 mL flexible container, 24 count (NDC 00338-1131-03)
10%, 500 mL flexible container, 24 count (NDC 00338-1130-03)
10%, 1000 mL flexible container, 12 count (NDC 00338-1130-04)
10%, 2000 mL flexible container, 6 count (NDC 00338-1130-06)
 
Prosol (sulfite-free) injection, Baxter
20%, 2000 mL flexible container, 6 count (NDC 00338-0499-06)
 
Travasol injection, Baxter
10%, 1000 mL flexible container, 12 count (NDC 00338-0644-04)
10%, 2000 mL flexible container, 6 count (NDC 00338-0644-03)
10%, 2000 mL flexible container (NDC 00338-0644-06)
 
TrophAmine injection, BBraun
6%, 500 mL glass container, 12 count (NDC 00264-9361-55)
10%, 500 mL glass container, 6 count (NDC 00264-9341-55)
 
Specialty Amino Acid Solutions
Aminosyn HBC (sulfite-free) injection, Hospira
7%, 500 mL flexible container, 12 count (NDC 00409-4168-03)
 
Aminosyn-RF (sulfite-free) injection, Hospira
5.2%, 500 mL flexible container, 12 count (NDC 00409-4166-03)
 
FreAmine HBC injection, BBraun
6.9%, 750 mL glass container, 6 count (NDC 00264-9350-55)
 
HepatAmine, BBraun
8%, 500 mL glass container, 6 count (NDC 00264-9371-55)
 
NephrAmine injection, BBraun
5.4%, 250 mL glass container, 6 count (NDC 00264-1909-55)
 
ProcalAmine injection, BBraun
1000 mL glass container, 6 count (NDC 00264-1915-07)

Estimated Resupply Dates

All marketed presentations are available.

Alternative Agents & Management

Amino acid shortage management strategies are available on the A.S.P.E.N. website.

Related Shortages

Updated

April 29 and 5, March 21, February 29 and 8, January 27 and 14, 2016; October 30, 23 and 7, September 24, July 15, June 10, May 26 and 14, April 27 and 16, March 11 and 4, 2015, University of Utah, Drug Information Service. Copyright 2016, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins

Advocacy Activity
Get the latest updates on ASHP's advocacy activity on drug shortages.
Advertisement
ASHP Product Listing